Rose, You are 100% correct - in principle - even it were based on fraud - the Du ruling should not have damaged Amarin at all - as it is addressing a different health issue. -----------------------
But that is theory - what we have experienced as 'Realty' - is that neither Generics or the US health system general 'Give a Damn' - what is on the label - or the name of the Icosapent Ethyl.
And what does 'Skinny Label' even mean. If what the patient wants is Icosapent Ethyl - the US logistic systems will 'automatically' provide him the cheapest Generic version (which you would have to guess right now is DR Reddy who has overtaken Hikma in no time).
Amarin and we as investors can scream as much as we like - no one really cares in the Systems - as it happens all over the place - all the time.
Generics are aloud to use every dirty trick in the book - WHY: It helps the States and Insurance companies save money on healthcare - end of story. ------------------------
Our immediate hope lies with Marjac and SCOTUS. Even this is naturally 'a long shot' (given the small number aloud through) - it is in fact precisely this problem he is addressing in his 'big filing' as I understand it.
Courts 'looking the other way' when generics cheat (the nice version) - because is is 'what the people on the hill wants'.
Market Data 
Markets 
AI
